Keith Crandell - 03 Apr 2023 Form 4 Insider Report for Quanterix Corp (QTRX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
04 Apr 2023, 18:23:24 UTC
Prior SEC filing
09 Feb 2023
Next SEC filing
16 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Brian Keane, as Attorney-in-Fact for Keith L. Crandell

Key filing fact

Keith Crandell filed Form 4 for Quanterix Corp (QTRX) on 04 Apr 2023.

Key facts

  • This page summarizes Keith Crandell's Form 4 filing for Quanterix Corp (QTRX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 04 Apr 2023, 18:23.

Change

  • Previous filing in this sequence was filed on 09 Feb 2023.
  • Current net transaction value: +$13,057.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QTRX transaction

Common Stock

Award

Transaction value
$13,057
Shares
+1,170
Change %
+0.9%
Price
$11.16
Shares after
131,236
Date
03 Apr 2023
Ownership
Direct
Footnotes
F1, F2, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the first quarter of 2023.

Footnote F2

Closing price of the Company's common stock on the Nasdaq Global Market on April 3, 2023.

Footnote F3

Includes 8,083 restricted stock units.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .